Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 1/20 | 0.32 |
| ▸ | FYN | P06241 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 5/20 | 0.32 |
| ▸ | CA12 | O43570 | 4/20 | 0.32 |
| ▸ | CA1 | P00915 | 4/20 | 0.32 |
| ▸ | CA2 | P00918 | 4/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17532215 | 1.00 | NR3C1 (0.32) | NR3C1FYNADRA2AADORA3ADRA2B | |
| SCHEMBL17521872 | 0.92 | NR3C1 (0.35) | NR3C1FYNADRA2AADORA3ADRA2B | |
| SCHEMBL19770013 | 0.92 | NR3C1 (0.35) | NR3C1FYNADRA2AADORA3ADRA2B | |
| SCHEMBL17521958 | 0.92 | NR3C1 (0.35) | NR3C1FYNADRA2AADORA3ADRA2B | |
| SCHEMBL15927274 | 0.92 | NR3C1 (0.35) | NR3C1FYNADRA2AADORA3ADRA2B | |
| SCHEMBL17521934 | 0.86 | CA2 (0.43) | NR3C1FYNADRA2AADORA3ADRA2B | |
| SCHEMBL9925400 | 0.85 | CA9 (0.36) | NR3C1FYNADRA2AADORA3ADRA2B | |
| SCHEMBL9925410 | 0.85 | CA2 (0.39) | NR3C1FYNADRA2AADORA3ADRA2B | |
| SCHEMBL15961753 | 0.83 | NR3C1 (0.35) | NR3C1FYNADRA2AADORA3ADRA2B | |
| SCHEMBL10028971 | 0.83 | NR3C1 (0.35) | NR3C1FYNADRA2AADORA3ADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9624255-B2 | Carbohydrate-mediated tumor targeting | ARIZONA BOARD OF REGENTS (US) | 2017-04-18 | — | — | US | disclosed |
| US-20120148502-A1 | Carbohydrate-Mediated Tumor Targeting | Arizona Board of Regents, a body corporate of the State of Ariz. acting for and on behalf of Ariz. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120148502-A1 | Carbohydrate-Mediated Tumor Targeting | CA14, CA13, CA12 | NR3C1 2710/4885FYN 2357/4885ADRA2A 3918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.